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CHAPTER 1: INTRODUCTION 
Obesity – A Global Epidemic 
Obesity is a global epidemic and its co-morbidities; including type 2 diabetes, 
cardiovascular disease, and metabolic syndrome, represent today’s major public health crises (1-
3).  Excessive food intake coupled with a sedentary lifestyle can, over time, contribute to obesity.  
According to the World Health Organization (WHO), individuals with a body mass index (BMI) of 
30 kg/m2 or more are considered obese (4).  In 2014, an estimated 600 million adults were obese, 
which is more than double what it was in 1980 (4). This overwhelmingly demonstrates the gravity 
of the exponentially growing obesity epidemic.  Figure 1 depicts the worldwide prevalence of 
obesity in adult men and women in 2014 (5,6).  Most of the regions of the world where the 
prevalence of obesity is the highest are associated with the Western Diet, which contains foods 
with high levels of saturated fats, starches, and sugars (7,8).  Individuals overindulging in this type 
of diet are more susceptible to becoming obese.  The health complications faced by the majority 
of people who are obese suffering from co-morbidities are overbearing and contribute to an overall 
lower quality of life and a shortened lifespan of about 20 years compared to non-obese individuals 
(9).  Based on 2006 data, medical costs associated with treating obesity were roughly $147 to 
$210 billion and accounted for more than 10% of all annual health care spending in the United 
States alone (10).  Based on the current trend, the financial burden of the treatment of obesity 
and its associated diseases is expected to increase.  Obesity is characterized by excess fat 
accumulation in the body, which often leads to health complications and morbidities.  Therefore, 
in order to combat this complex condition, it is imperative to research the molecular mechanisms 







Figure 1: Worldwide prevalence of obesity in 2014 of adult men and women. 
 
The World Health Organization depicts the global prevalence of obesity in the year 2014 of adult 




Functions of Adipose Tissue 
Adipose tissue is composed of adipocytes, or fat cells, pre-adipocytes, resident 
macrophages, fibroblasts, and endothelial cells (11).  The two main types of adipose tissue are 
brown and white.  Brown adipose tissue is multilocular and contains numerous mitochondria that 
oxidize fatty acids in order to produce heat to keep the body warm (12).  Although brown adipose 
tissue is prevalent in newborns and infants, there is very little in human adults (12).  White adipose 
tissue is unilocular and can be subcutaneous or visceral, which is primarily in the abdominal 
region.  The primary function of white adipose tissue is to store fat as triglycerides for use during 
periods of high energetic demand and low calorie intake in a lipid droplet within the adipocytes.  
The white adipose tissue also serves as an endocrine organ.  White adipose tissue is the focus 
of this study. 
Fat deposition and Fat mobilization  
White adipose tissue is responsible for regulating energy homeostasis through the 
processes of lipogenesis and lipolysis.  Lipogenesis is the process of storing fat as triglycerides 
in the lipid droplet of adipocytes.  The lipid droplet has a hydrophobic core containing triglycerides 
and cholesterol that is contained by a monolayer of phospholipids (13).  The diameter of the lipid 
droplet typically ranges from 20-100 μm and often occupies the majority of the cell’s volume (14).  
A triglyceride (TG) is a molecule that has three fatty acids attached to a glycerol backbone.  The 
fat that is stored in the lipid droplets of adipocytes is derived from fatty acids that are absorbed in 
the diet or from fatty acid synthesis in the liver (15).  When food is digested, lipases in the small 
intestine breakdown the TGs into fatty acids, which are then absorbed along with sugars, proteins, 
and other nutrients by the small intestine.  The fatty acids are converted back to TGs and 
packaged into a lipoprotein known as a chylomicron for transport to other parts of the body.  The 
apolipoprotein B (ApoB) on the chylomicron activates the lipoprotein lipase (LPL) in the capillaries, 
which hydrolyzes the TGs into glycerol and fatty acids (16).  The majority of these fatty acids are 
taken up by the adipocytes and re-esterified to form TGs for storage in the lipid droplet.  De novo 
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lipogenesis involves synthesizing fatty acids from glucose in the liver.  These fatty acids are 
converted to TGs, packaged into very low density lipoproteins (VLDLs), and released into the 
bloodstream.  Like chylomicrons, the VLDLs possess ApoB that activates the LPL, triggering the 
hydrolysis of TGs into glycerol and fatty acids (16).  These fatty acids are taken up by the 
adipocytes, re-esterified into TGs, and stored in the lipid droplet of the adipocytes. 
 Conversely, lipolysis is the breakdown of the triglycerides that are stored in the lipid 
droplets of the adipocytes into glycerol and free fatty acids.  When the body is in the fasting state 
or when energy is in high demand, lipolysis is stimulated.  A series of lipases hydrolyze the TGs 
into glycerol and fatty acids that are then released into the bloodstream.  Upon exiting the 
adipocyte, the fatty acids bind to albumin and travel to different tissues, such as the liver and 
skeletal muscle.  There, they are used as substrates to produce adenosine triphosphate (ATP), 
the cell’s main form of energy (12,17).  In addition to energy production, the released fatty acids 
can be used as scaffolds for cell membrane phospholipids or for the synthesis of bioactive lipid 
mediators (18).  The molecular mechanism of lipolysis will be described in detail in the Lipolysis 
section of the Introduction. 
The balance of lipogenesis and lipolysis and their intricate molecular signaling pathways 
are carefully regulated by the responses of the adipocytes to hormones.  Immediately after a 
meal, insulin is secreted from the pancreas and stimulates lipogenesis in the body.  Insulin not 
only stimulates the LPL, but is also involved in activating the glucose transporters in different 
tissues that facilitate the uptake of glucose for storage and use at a later time.  In the fasting state, 
glucagon and catecholamines stimulate lipolysis in the adipose tissue, which causes the 
mobilization of nutrients and provides the body with energy. 
In addition, one’s overall health and energy homeostasis can be affected by the type of 
fatty acids consumed in the diet that are stored in the adipocytes and incorporated in cell 
membranes.  Omega-3 and omega-6 fatty acids are considered essential fatty acids because 
they are unable to be synthesized in humans and must be obtained through the diet (19).  The 
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difference between these types of fatty acids is the position of the double bond from the methyl 
end of the fatty acid’s molecular structure.  The Western diet, consisting mainly of red meat, eggs, 
and processed food, has high levels of omega-6 fatty acids.  High levels of omega-6 fatty acids 
have been shown to produce pro-inflammatory effects and promote cardiovascular disease, 
different kinds of cancer, and rheumatoid arthritis (18,19).  On the contrary, omega-3 fatty acids, 
such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that are commonly found 
in fish, cod liver oil, and flaxseed oil, have been shown to produce anti-inflammatory effects and 
help fight these diseases (20).  The omega-6 to omega-3 fatty acid ratio is overwhelmingly high 
in the Western diet; 20-30:1 versus the ideal 1:1 ratio (21).  In regards to energy homeostasis, 
studies suggest that omega-3 fatty acids play a role in down-regulating genes involved in 
lipogenesis leading to decreased fat accumulation (15,22,23).  For example, in 3T3-L1 mouse 
adipocytes, DHA and EPA have been shown to reduce the activity of stearoyl-CoA desaturase 
(24,25) and EPA shown to down-regulate glucose-3-phosphate dehydrogenase activity (26).  Fish 
oil fed rats displayed significantly lower plasma triglyceride levels and decreased LPL activity in 
the adipose tissue, demonstrating a favorable increase in fatty acid oxidation (15,27).  Additional 
research has shown that DHA treatment can increase basal lipolysis in 3T3-L1 mouse adipocytes 
by up-regulating the adipose triglyceride lipase (ATGL), a key enzyme in the lipolysis process 
(24).  Incorporating EPA in the differentiation process of 3T3-L1 adipocytes resulted in smaller 
lipid droplets and an up-regulation of hormone sensitive lipase (HSL) gene expression (25).  
Therefore, diet is influential in affecting lipid metabolism and energy homeostasis. 
Endocrine Organ 
Adipose tissue is not only utilized for storing triglycerides, but it also functions as an 
endocrine organ that produces and secretes cytokines, chemokines, and other signaling 
mediators, known as adipokines, into the bloodstream (12,28,29).  Adipokines carry out their 
physiological functions in an autocrine, paracrine, or systemic manner by binding to their 
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respective receptors.  Leptin and adiponectin represent two adipokines that are involved in energy 
homeostasis and glucose and lipid metabolism (29).   
In 1994, Dr. Jeffrey M. Friedman’s laboratory at Rockefeller University identified the first 
adipokine, leptin, as the missing gene in the grossly obese ob/ob mice (30).  The name, leptin, 
comes from the Greek term, leptos, meaning thin (28,29).  When leptin is secreted by the adipose 
tissue, it activates its receptors in the hypothalamus and in the adipose tissue to control appetite 
and promote fatty acid oxidation, respectively (31,32).  Although leptin exhibits favorable effects 
at normal quantities, high levels of leptin are found in obese individuals (33,34).  The increased 
fat accumulation in obesity leads to the desensitization of the body to leptin, disrupting the 
homeostasis of energy metabolism (35). 
Unlike leptin, there is an inverse correlation between the levels of circulating adiponectin 
in the plasma and body mass (36,37).  Therefore, adiponectin is high in healthy individuals and 
low in obese subjects.  Low levels of adiponectin are associated with diseases such as diabetes 
mellitus, hypertension, cardiovascular diseases, and metabolic syndrome (38-40).  In fact, in 
2001, Yamauchi et al. discovered that adiponectin treatment lowered plasma triglycerides, 
increased fatty acid oxidation, and improved the insulin resistance endured by the KKAy and 
db/db mice (41).  Adiponectin has also been shown to inhibit the activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NFĸB), a transcription factor involved in multiple 
inflammatory signaling pathways (42), and decrease the expression of monocyte adhesion 
molecules in the endothelium (43), therefore resulting in anti-inflammatory and anti-
atherosclerotic effects. 
Tumor necrosis factor α (TNFα), interleukin-6 (IL-6), plasminogen activator inhibitor 1 
(PAI-1), and monocyte chemotactic protein 1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) are 
pro-inflammatory adipokines that contribute to the initiation and exacerbation of adipose tissue 





Obesity involves excess fat accumulation and chronic low-grade inflammation in the 
adipose tissue (3,18,44).  This chronic low-grade inflammation is characterized by a significant 
production of pro-inflammatory cytokines followed by the recruitment and activation of 
macrophages in the adipose tissue (45).  When the caloric intake consistently exceeds the caloric 
expenditure, an excess amount of fat is stored in the lipid droplet causing the adipocytes to 
expand and possess a hypertrophied phenotype.  It has been reported that the lipid droplet has 
the ability to expand up to 1000 times its normal volume and 10 times its diameter to 
accommodate the fat storage (46).  The distended lipid droplet causes the nuclei of the adipocytes 
to be pushed to the perimeter of the cell causing physical strain and stress on the cell membrane.  
The hypertrophied adipocytes in obese adipose tissue produce and secrete significantly high 
levels of pro-inflammatory cytokines, including TNFα, IL-6, PAI-1, and MCP-1/CCL2, and very low 
amounts of anti-inflammatory cytokines, compared to adipose tissue seen in lean, healthy 
individuals (47). 
Pro-inflammatory cytokines 
TNFα was first recognized as a cytokine produced by macrophages that had antagonistic 
effects against tumors, thus its name, tumor necrosis factor α (48).  Since then, TNFα has been 
shown to be highly expressed in the adipose tissue of obese subjects (49,50) and play critical 
roles in stimulating inflammation and insulin resistance.  TNFα binds to its receptor and activates 
NFĸB, triggering multiple inflammatory cascades (28), and impairs insulin signaling in the skeletal 
muscle and adipose tissue by interfering with the phosphorylation of insulin receptor substrate 1 
(IRS-1) (28,51).  In addition, TNFα has been linked to increased rates of atherosclerosis (52).  
Therefore, up-regulated TNFα expression is associated with many adverse effects in the adipose 
tissue and the whole body. 
 Another inflammatory adipokine is interleukin-6.  High levels of circulating IL-6 have been 
linked to obesity and glucose intolerance (28,53).  The overall effects of IL-6 on adiposity and 
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insulin resistance differ in the peripheral versus central nervous system.  Peripheral administration 
of IL-6 has been shown to inhibit insulin signaling, thus contributing to insulin resistance, and to 
reduce the production of adiponectin (54,55).  In contrast, central administration of IL-6 has 
displayed a decrease in adiposity and increased energy expenditure (56).  Further research is 
warranted on the physiological functions and involvement of IL-6 in cell signaling pathways.  
Plasminogen activator inhibitor 1 is produced and secreted from the adipose tissue and 
blocks the functions of urokinase plasminogen activator (uPA) and tissue plasminogen activator 
(tPA) (28).  As a result, the breakdown of fibrin is inhibited.  High levels of PAI-1 are associated 
with obesity (57), insulin resistance (58), and myocardial infarctions (59).  The oral PAI-1 
antagonist, tiplaxtinin, has been shown to ameliorate insulin resistance and reduce fat 
accumulation, but due to the risk of toxic and adverse effects, is not used commercially (60).  
Consequently, PAI-1 is another adipokine that produces undesirable effects at abnormal levels. 
Monocyte chemotactic protein 1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) is 
significantly increased in obesity and is responsible for recruiting monocytes and macrophages 
to the hypertrophied adipose tissue (61).  MCP-1/CCL2 acts by binding its receptor, CCR2, 
expressed on the monocytes (29).  In 2006, Dr. Stuart Weisberg’s laboratory showed that the 
mice lacking CCR2 fed a high fat diet possessed improved insulin resistance, reduced body 
weight and macrophage accumulation, and down-regulated inflammatory genes in the adipose 
tissue (62).  The Weisberg laboratory also administered a pharmacological CCR2 inhibitor to diet-
induced obese mice and found significantly reduced macrophage accumulation in the adipose 
tissue (62).  Therefore, MCP-1/CCL2 plays a critical role in the development of adipose 
inflammation. 
The pro-inflammatory cytokines released from the hypertrophied adipocytes can also 
activate the endothelial cells in the adipose tissue (47).  As a consequence, the endothelial cells 
produce cell adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular cell adhesion molecule 1 (ICAM-1), that facilitate the attachment of monocytes to the 
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endothelial cell wall and their passage through the cell-cell junctions into the adipose tissue (47).  
As reported by Claudio Ferri et al in 1999, circulating levels of VCAM-1 and ICAM-1 are 
significantly higher in obese adults (63).  Therefore, the activation of the endothelium contributes 
to inflammation in the adipose tissue. 
Macrophages 
Due to the up-regulated gene expression of MCP-1/CCL2 in hypertrophied adipose tissue, 
there is a mass accumulation of macrophages that are recruited to the adipose tissue in obese 
mice and humans (64).  In fact, the amount of macrophages in the adipose tissue is directly related 
to an individual’s BMI (64).  The recruited macrophages possess a different phenotype than the 
macrophages that already reside in the adipose tissue.  The resident macrophages are 
“alternatively activated” by cytokines, interleukin-4 and interleukin-13, and possess an M2 
phenotype (65).  The M2 macrophages express an arginase enzyme that blocks the inducible 
nitric oxide synthase (iNOS) and also produce anti-inflammatory cytokines (65).  The recruited 
macrophages have an M1 phenotype and are “classically activated” by interferon gamma (INF-γ) 
or lipopolysaccharide (LPS) (65).  The M1 macrophages produce high levels of pro-inflammatory 
cytokines, reactive oxygen species (ROS), and trigger iNOS reactions (65).  The different 
macrophage phenotypes are associated with different metabolic properties.  M1 macrophages 
induce insulin resistance by inhibiting glucose uptake in response to insulin, whereas M2 
macrophages enhance insulin signaling (66).  The majority of macrophages found in lean, healthy 
individuals possess the M2 phenotype whereas an abundance of M1 macrophages are seen in 
obese individuals (67).  Therefore, it has been suggested that the macrophages in obese adipose 
tissue undergo a phenotypic conversion from M2 to the inflammatory, M1 phenotype (66,67).  
However, as described by Dr. Carey Lumeng et al in 2008, this switch is more likely linked to 
differential macrophage recruitment (66).  Macrophages can produce and release pro-
inflammatory cytokines that recruit more macrophages to the adipose tissue as well as activate 
the endothelium, promoting their own attachment and diapedesis. 
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Hypoxia and ER Stress 
Due to the enlarged size of the adipocytes in obese adipose tissue, the blood flow carrying 
necessary oxygen and nutrients to the cells is limited.  When the availability of the oxygen and 
nutrients do not meet the demands of the cells, localized hypoxia and necrotic cell death could 
occur (68).  A histologic characteristic of necrotic cell death in the adipose tissue is the formation 
of “crown-like” structures by the macrophages (69).  Most of the M1 macrophages recruited to the 
adipose tissue aggregate and surround the dead or dying adipocytes (66).  In 2005, Dr. Saverio 
Cinti et al reported that the rate of adipocyte necrosis is directly related to the size of the 
adipocytes and takes place about 30 times more in in obese humans and mice models (69). 
 In addition, hypoxia induces stress on organelles such as the endoplasmic reticulum (ER) 
in the adipocytes.  ER stress is initiated when hypoxia, toxins, excess nutrition, or energy 
deprivation, disrupts the ER’s ability to properly assemble proteins, causing a build-up of unfolded 
proteins (70).  ER stress has been shown to occur in obese adipose tissue and generate high 
levels of ROS that cause oxidative damage to lipids, proteins, and DNA (71).  Mitochondria also 
produce elevated amounts of ROS in obesity and together, the two organelles perpetuate the 
oxidative stress and damage in the cells (72).  In an attempt to reestablish homeostasis, the ER 
activates a coordinated series of signaling pathways that serve as a protective mechanism known 
as the unfolded protein response (UPR) (71).  The UPR is mediated by three transmembrane 
proteins in the ER: inositol-requiring kinase 1 (IRE-1), pancreatic ER kinase (PERK), and 
activating transcription factor 6 (ATF6).  If the ER stress in the cell is unable to be corrected, 
apoptosis signaling pathways are initiated (70). 
Excessive lipolysis 
In addition, the hypertrophied adipocytes in obese adipose tissue undergo excessive 
lipolysis (73,74) and secrete abnormally high levels of free fatty acids into the bloodstream 
(75,76).  The surplus of free fatty acids is in part due to the adipose tissue’s compromised 
sensitivity to insulin, which would normally inhibit lipolysis (23).  The fatty acids released from the 
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visceral adipose tissue enter the portal vein that travels directly to the liver (77).  When the influx 
of fatty acids exceeds the oxidation capacity in the liver, triglyceride synthesis increases and 
hepatosteatosis (fatty liver) occurs (77).  Hepatosteatosis is a form of lipotoxicity, which is a 
condition where fatty acids infiltrate and accumulate in different organs of the body other than the 
adipose tissue.  Hepatosteatosis can progressively worsen into non-alcoholic steatohepatitis 
(NASH) or non-alcoholic liver disease (NALD) or even cause permanent damage and scarring 
(cirrhosis) in the liver (77).  Fatty liver is a common occurrence in not only obese individuals but 
also those who are glucose intolerant or have diabetes mellitus.  The buildup of triglycerides 
inhibits the ability of organs such as the liver and skeletal muscle to respond to insulin and take 
in glucose, therefore contributing to insulin resistance (18).  Overtime, the beta cells in the 
pancreas will “burnout” from constantly producing and secreting insulin, which will result in 
diabetes mellitus.   
Free fatty acids can also activate toll-like receptor 4 (TLR4) that is expressed in adipocytes 
and macrophages, resulting in the production of pro-inflammatory cytokines (78).  The expression 
of TLR4 has been shown to be up-regulated in the adipose tissue of obese mice (61,78).  TLR4 
activation stimulates pathways that include c-jun N-terminal kinase (JNK) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFĸB), which often lead to inflammation and 
insulin resistance.  JNK can be activated by a variety of stimuli including pro-inflammatory 
cytokines, fatty acids, ROS, and oxidative stress (70,72).  In obese animals, JNK activity has been 
shown to be significantly increased in the adipose tissue (79).  JNK and IKKβ are serine/threonine 
kinases that, when activated, can interfere with the phosphorylation of the insulin receptor 
substrate 1 (IRS-1), thus contributing to insulin resistance.  Therefore, excessive fatty acids that 
are released from recurrent lipolysis contribute not only to adipose tissue inflammation, but also 




The culmination of the hypertrophied adipocytes, pro-inflammatory cytokines, ER and 
oxidative stress, the elevated free fatty acids from excessive lipolysis, the up-regulated cell 
adhesion molecules in the endothelium, and the recruitment and activation of macrophages 
exacerbates inflammation in the adipose tissue.  All of these factors are inter-related and cause 
adipose inflammation, insulin resistance, and a disruption in the ability of the adipose tissue to 
function properly.  The involvement of the signaling molecules and mediators in chronic obesity 
can be recaptured by the acute activation of the beta-3 adrenergic receptor-mediated lipolysis in 
mouse adipocytes, which is discussed in the next section of the Introduction.  Therefore, the 
activation of the beta-3 adrenergic receptor-mediated lipolysis provides a tractable model for 

















Figure 2: The progression of inflammation in adipose tissue. 
 
As described by Wellen et al in the Journal of Clinical Investigation, persistent overeating causes 
large amounts of fat to be stored in the adipocytes causing them to become hypertrophied.  The 
enlarged adipocytes secrete pro-inflammatory cytokines and chemokines, such as TNFα and 
MCP-1, which recruit macrophages to the adipose tissue.  In addition, lipolysis occurs in excess 
in inflamed adipose tissue and the surplus free fatty acids could lead to oxidative stress.  The 
macrophages, hypertrophied adipocytes, and the endothelium produce and secrete more pro-
inflammatory cytokines that recruit more macrophages to the adipose tissue, which exacerbates 












Lipolysis is initiated through the stimulation by catecholamines of the beta-adrenergic 
receptors (β1-3) that are expressed in the adipocytes (81).  The beta-adrenergic receptors are G-
protein coupled receptors that are associated with the Gs protein, which activates the adenylyl 
cyclase.  In the adipose tissue, the β1 and β2-adrenergic receptors are mostly expressed and 
active in humans, while the β3-adrenergic receptor is predominantly expressed and active in 
rodents (82). 
In order to study the signaling molecules and mediators involved in lipolysis, I used the well-
studied, β3-adrenergic receptor (ADRB3)/hormone sensitive lipase (HSL)-signaling model in 
mouse adipocytes (83,84).  The two chemical agonists that were used to stimulate the ADRB3 
were isoproterenol (ISO) and CL 316-243 (CL).  ISO is a non-selective beta-adrenergic receptor 
agonist that was used in the in vitro experiments with the 3T3-L1 mouse adipocyte cell line.  CL 
is an agonist selective for the ADRB3 and was used in the in vivo experiments with the C57BL/6 
mice.  Following the stimulation of the ADRB3, hormone sensitive lipase, a key enzyme in the 
lipolytic process, is activated.  BAY 59-9435 (BAY) is a selective HSL antagonist that was used 
in the in vitro and in vivo experiments (83). 
When the ADRB3 is stimulated with ISO or CL, its associated Gs protein activates the adenylyl 
cyclase.  Adenylyl cyclase converts adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP).  The increased levels of cAMP act as a second messenger to activate 
protein kinase A (PKA), which phosphorylates hormone sensitive lipase (HSL) and perilipin-1 
(Plin1), a lipid droplet surface protein.  In the basal state, comparative gene identification-58 (CGI-
58), the co-activator of adipose triglyceride lipase (ATGL), is bound to the non-phosphorylated 
Plin1 (85).  The phosphorylation of Plin1 causes CGI-58 to dissociate, allowing CGI-58 to interact 
with ATGL, maximizing ATGL’s activity (86).  The phosphorylation of HSL causes HSL to 
translocate from the cytosol to the surface of the lipid droplets containing Plin1 (86).  The 
breakdown of a triglyceride molecule by a series of lipases takes place on the surface of the lipid 
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droplet as follows.  A triglyceride is hydrolyzed by ATGL, resulting in one free fatty acid and 
diglyceride.  Diglyceride is hydrolyzed by HSL, resulting in one free fatty acid and monoglyceride.  
Monoglyceride is hydrolyzed by monoglyceride lipase (MGL), resulting in one free fatty acid and 
glycerol.  The majority of the glycerol and fatty acids are released into the bloodstream where 
they bind to albumin and travel to the liver and skeletal muscle for beta oxidation in order to 
provide the cells with energy (12,17).  When lipolysis occurs in excess, as seen in obesity, the 
abundance of free fatty acids in circulation leads to an accumulation of fatty acids in the liver, 
heart, or other organs, causing lipotoxicity.  The high levels of fatty acids contribute to the severity 
of the inflammation in the adipose tissue. 
Mutations and genetic defects in the molecular players of lipolysis result in debilitating 
diseases.  Mice lacking the PNPLA2 (ATGL) gene have been shown to exhibit significant 
triglyceride accumulation in multiple organs including the heart and die prematurely due to heart 
failure (87).  On the contrary, transgenic mice overexpressing the PNPLA2 gene display increased 
rates of lipolysis and fatty acid oxidation in the adipose tissue (88).  Humans with a defect in the 
PNPLA2 gene suffer from Neutral Lipid Storage Disease with Myopathy (NLSDM).  Similar to the 
clinical manifestations in PNPLA2 null mice, humans with NLSDM have triglyceride accumulations 
throughout the body, an enlarged liver, and suffer from cardiovascular diseases (89).  Humans 
with a mutated CGI-58 gene suffer from Chanarin-Dorfman Syndrome.  Those affected have 
triglyceride accumulations throughout the body due to the weakened ATGL activity, mild 
myopathy, and ichthyosis (89). 
Hormone sensitive lipase knock out mice have an accumulation of diglycerides due to the 
disruption in the lipolytic process.  Although they have hypertrophied adipocytes containing an 
increased number of macrophages, they are resistant to high fat diet-induced obesity and instead 
have elevated thermogenesis in their more pronounced brown adipose tissue (90).  In humans, a 
mutation in the LIPE gene that encodes the HSL protein causes symptoms that are less prominent 
than those experienced in NLSDM (91).  Even though those affected are not obese, they develop 
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partial lipodystrophy as they age and are diabetic (91).  Furthermore, they have a fatty liver, a 
high plasma triglyceride count, and down-regulated genes involved in lipogenesis and lipid 
synthesis (91).  Therefore, when lipolytic genes are mutated or defective, the energy homeostasis 
and lipid metabolism processes are disrupted.  The clinical manifestations of these genetic 













Figure 3: Mechanism of lipolysis in adipocytes. 
 
As described in Luglio et al in the Journal of Clinical Biochemistry and Nutrition, in the basal state, 
perilipin is bound to CGI-58, the coactivator of adipose triglyceride lipase (ATGL), on the surface 
of the lipid droplet in the adipocytes.  Upon phosphorylation of perilipin by protein kinase A (PKA), 
perilipin dissociates from CGI-58 which allows CGI-58 to associate with ATGL and maximize its 
activity.  Hormone sensitive lipase (HSL) is also phosphorylated by PKA and translocates from 
the cytosol to the surface of the lipid droplet in close association with perilipin.  The triglycerides 
are hydrolyzed by a series of lipases; ATGL, HSL, and monoglyceride lipase (MGL), into free fatty 












The involvement of lipids in adipose tissue inflammation is of interest to scientists in the 
lipidomic field.  Eicosanoids are a class of lipids derived from omega-3 and omega-6 fatty acids 
that have numerous physiological functions that contribute to homeostasis or the pathogenesis of 
many diseases, including cancer, inflammation, asthma, and autoimmune diseases (93).  The 
name, eicosanoid, is derived from the Greek word, eicosa, meaning twenty, because most of the 
eicosanoids have 20 carbons in their molecular structure (94).  The specific eicosanoids and the 
amounts produced are dependent on the type of cell and tissue.  When a cell is exposed to an 
external stimuli, such as growth factors, hormones, or cytokines, phospholipase A2 (PLA2) and 
phosopholipase C (PLC) are activated (93).  PLA2 cleaves membrane phospholipids at the sn-2 
position releasing arachidonic acid, EPA, and DHA which are then used as substrates for the 
biosynthesis of eicosanoids (18).  PLC cleaves the membrane phospholipid releasing 
diacylglyceride.  Free fatty acids are readily metabolized into lipid mediators and exert their effects 
by binding to their respective receptors.  The types of dietary fatty acids incorporated into the cell 
membranes dictate the types of eicosanoids produced and their physiological properties.  The 
omega-3 fatty acids, EPA and DHA, and their derivatives exert anti-inflammatory effects, while 
metabolites from the omega-6 fatty acid, arachidonic acid, are mostly pro-inflammatory, with the 
exception of the lipoxins. 
 Arachidonic acid is metabolized by three main enzymatic pathways: cyclooxygenase 
(COX), lipoxygenase (LOX), and cytochrome P450 (see Figure 4).  The COX enzyme produces 
prostaglandins, prostacyclins, and thromboxanes.  The COX enzyme and its derivatives will be 
described in detail in the next section.  The LOX enzymes produce hydroperoxyeicosatetraenoic 
acids (HPETEs), which are reduced by peroxidases to the corresponding 
hydroxyeicosatetraenoic acids (HETEs).  Leukotrienes and lipoxins are also metabolites of the 
LOX enzymatic family.  The cytochrome P450, or epoxygenase, enzymes produce 




Figure 4: Arachidonic acid metabolism and the generation of eicosanoids.   
 
As described in Harizi et al in Trends in Molecular Medicine, upon exposure of an external 
stimulus, phospholipase A2 (PLA2) is activated and cleaves the cell membrane phospholipids, 
releasing arachidonic acid.  Arachidonic acid is metabolized by three main families of enzymes: 
cyclooxygenase (COX), responsible for producing prostaglandins, prostacyclins, and 
thromboxanes; lipoxygenase (LOX), which produces HPETEs, that are reduced to HETEs, 













The cyclooxygenase (COX) enzyme, also known as prostaglandin H synthase, was first 
discovered using extracts of seminal vesicles from sheep (95).  Extensive research revealed that 
the COX enzyme has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2).  
In humans, the amino acid sequences of COX-1 and COX-2 are approximately 60% identical (96).  
The crystal structures of COX-1 and COX-2 also appear similar, however, COX-2 has a larger 
active site than COX-1 (97).  The COX-2 gene has a TATA box and NFĸB as an inducible 
enhancer element, which are not present in COX-1 (97).  COX-1 is considered a “housekeeping” 
gene and is constitutively expressed in the majority of tissues in the body, whereas the COX-2 
isoform is barely detected in most tissues and is an inducible gene that is stimulated by pro-
inflammatory cytokines or mitogens.  Both isoforms use their cyclooxygenase activity to transform 
arachidonic acid to prostaglandin G2 (PGG2), which is then rapidly converted to prostaglandin 
H2 (PGH2) by the COX enzyme’s peroxidase activity (98).  PGH2 is converted into different 
species of prostanoids, which include prostaglandins (PGD2, PGE2, PGF2α, d15-PGJ2 
(dehydrated form of PGD2)), prostacyclin (PGI2), and thromboxane (TXA2) by specific enzymes.  
The most abundant prostaglandin is PGE2.  Each of these bioactive metabolites have different 
chemical structures, varying functions, and mediate multiple cell signaling pathways. 
The prostanoids derived from COX-1 are predominantly involved in regulating 
homeostasis and normal physiological functions in the body (99).  For instance, PGE2 and PGI2 
are involved in protecting the gastrointestinal and renal tracts, and the tone of the vasculature is 
influenced by the vasodilator actions of PGE2 and the vasoconstriction of PGF2α (99).   The 
levels of prostacyclin (PGI2) and TXA2 dictate platelet function, as the former inhibits platelet 
aggregation and the latter triggers it (99).  Prostaglandins have also been shown to be involved 
in regulating the sleep/wake cycle in the brain and inducing uterine contractions during labor 
(99,100).  Moreover, 15d-PGJ2 is a potent PPAR-gamma agonist and mediates cell injury (101).  
Therefore, prostanoids have roles in regulating homeostatic functions in the body.  
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The prostanoids produced by the COX-2 isoform are predominantly involved in regulating 
inflammation in the body (99).  COX-2 has been shown to be significantly up-regulated in 
pathological diseases such as rheumatoid arthritis and colon cancer (102,103).  As a result, PGE2 
is abundantly present and is hypothesized to play a role in the development of these diseases.  
COX-2 expression is also associated with the presence of the amyloid β peptide in Alzheimer’s 
disease (104).  In addition, myocardial infarctions and strokes are more likely to occur when there 
are disproportionate levels of PGI2 and TXA2 (105).  Therefore, the dysregulation of 
prostaglandins by the COX enzyme contributes to the pathogenesis of inflammatory diseases and 
cancers. 
In 1898, the first non-steroidal anti-inflammatory drug (NSAID), aspirin, was put on the 
market for its anti-inflammatory effects.  It wasn’t until the early 1970s that scientists discovered 
that the mechanism of aspirin was the inhibition of the COX enzyme and its prostaglandin 
derivatives (106).  Non-selective NSAIDs inhibit the cyclooxygenase activity of COX-1 and COX-
2 by binding to the active site.  NSAIDs are blood thinners and exert antipyretic, analgesic, and 
anti-inflammatory effects (107).  They have a protective effect from gastric and colorectal cancer, 
and even Alzeheimer’s disease (96,108).  The main adverse side effects associated with NSAIDs 
are gastric bleeding and ulcerations.  This led to the development of a new class of selective 
NSAIDs that specifically inhibit COX-2 activity, known as the “coxibs”.  In 1999, celecoxib and 
rofecoxib were commercially introduced as the first selective COX-2 NSAIDs (109).  Celecoxib 
and rofecoxib were prescribed to treat patients with arthritis and painful joints and to prevent the 
development of colon cancer (100,110).  The GI and renal side effects seen in the non-selective 
NSAIDs were considerably improved, however, the platelet aggregation associated with this class 
of drugs created a significant cardiovascular risk; so much so that rofecoxib was removed from 
the market (105).  Nevertheless, medications that block the activity of the COX enzyme, 
particularly the COX-2 isoform, in order to reduce inflammation are taken by millions of people 
around the world on a daily basis (108).   
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Significance and Objective 
Although the roles of cytokines and other proteins in adipose tissue inflammation and 
lipolysis have been well studied, little is known about the involvement of bioactive lipid mediators.  
The identity of the specific bioactive lipids that are generated from adipocyte lipolysis are unknown 
and the physiological functions and roles they may play in pro-inflammatory signaling pathways 
in the adipose tissue are unclear.  Research in this area would not only expand our knowledge in 
the lipidomic field in regards to adipose biology, but also reveal new signaling mechanisms that 
occur in adipose inflammation.  A lipidomic approach would potentially produce novel findings 
and avenues for therapeutic targets for improving obesity and adipose inflammation in the future.  
The therapeutic strategies could include enhancing the activity of enzymes or specific bioactive 
lipids that exert anti-inflammatory effects or inhibiting those that produce adverse effects.   
The objective of my doctoral research project was to characterize the adipose lipolysis-
derived eicosanoid lipid mediators through the acquisitions and analyses of lipidomic profiles 
using the latest LC-MS/MS methods.  Further investigation led to the discovery of a signaling 














CHAPTER 2:  METHODS AND MATERIALS 
Reagents 
The beta adrenergic receptor agonist, isoproterenol (ISO) (Sigma), was dissolved in H2O.  
The selective hormone sensitive lipase inhibitor, BAY 59-9435 (BAY), was chemically synthesized 
as described (111) and dissolved in 0.5% methylcellulose.  The selective beta-3 adrenergic 
receptor agonist, CL 316-243 (CL) (Sigma), was dissolved in H2O.  The cyclooxygenase-2 
inhibitor, celecoxib (Sigma), was dissolved in DMSO.  The JNK inhibitor (SP-600125, 
Calbiochem), p38 inhibitor (SB 203580, Calibochem) and NFĸB inhibitor (BAY 11-7082, 
Calbiochem) were dissolved in DMSO.  The palmitic acid (Sigma) was dissolved in 0.4% fatty 
acid free fetal bovine serum (FBS).  Antibodies against COX-1, COX-2, phospho-JNK, JNK, 
phospho-IĸBα, IĸBα, phospho-HSL, and HSL were from Cell Signaling.  The polyclonal rabbit anti-
F4/F80 and anti-GAPDH were purchased from Abcam and Santa Cruz, respectively.  Other 
reagents, unless specified, were from Sigma. 
Cell culture 
3T3-L1 and 3T3-L1-CAR cells were cultured and differentiated as previously described 
(84,112).  Briefly, 3T3-L1 cells were cultured to about 80% confluency in DMEM medium with 
10% bovine calf serum (BCS) and 1% penicillin/streptomycin antibiotic.  Differentiation involved 
incubating the cells in DMEM medium (containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin) with 1 µg/ml insulin, 0.5 mM methylisobutylxanthine (MIX), and 0.25 µM 
dexamethasone (DEX) for three days.  Next, the cells were incubated with DMEM medium 
(containing 10% FBS and 1% penicillin/streptomycin) with 1 µg/ml insulin for 48 hours.  Two days 
post-differentiation, cells were cultured overnight in serum-free DMEM.  Subsequently, media 
were replaced with phenol red free plain DMEM.  Cells were treated with 10 µM of ISO or PBS 
control for 3 hours at 37⁰C.  Alternatively, cells were pretreated with a selective HSL inhibitor (BAY 
59-9435, 10 µM), JNK inhibitor (SP-600125, 10 µM), p38 inhibitor (SB 203580, 10 µM), NFκB 
inhibitor (BAY 11-7082, 10µM), or cyclooxygenase-2 inhibitor (celecoxib, 5 µM) for 1 hour, 
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followed by stimulation with ISO (10 µM) or PBS control for an additional 3 hours.  Cell pellets 
and culture media were collected and processed for biochemical analysis and lipid quantification 
by LC-MS/MS methods, respectively, as described below.  Transduction of 3T3-L1-CAR cells with 
adenoviral particles was performed essentially as previously described (112). 
Sample preparation for LC-MS/MS analysis of lipid mediators 
Samples (0.85 ml) were spiked with 5 ng each (in 150 µl methanol) of 15(S)-HETE-d8, 
14(15)-EpETrE-d8, Resolvin D2-d5, Leukotriene B4-d4, and Prostaglandin E1-d4 as internal 
standards for recovery and quantitation and mixed thoroughly.  The samples were then extracted 
for PUFA metabolites using C18 extraction columns as described earlier (113-115).  Briefly, the 
internal standard spiked samples were applied to conditioned C18 cartridges, washed with 15% 
methanol in water followed by hexane and dried under vacuum.  The cartridges were eluted with 
0.5 ml methanol.  The eluate was dried under a gentle stream of nitrogen.  The residue was 
dissolved in 50 µl methanol-25 mM aqueous ammonium acetate (1:1) and subjected to LC-MS 
analysis. 
LC-MS/MS quantification 
HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3µ, 
2.1x150 mm) column.  The mobile phase consisted of a gradient between A: methanol-water-
acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile (90:5:5 v/v), both containing 0.1% 
ammonium acetate.  The gradient program with respect to the composition of B was as follows: 
0-1 min, 50%; 1-8 min, 50-80%; 8-15 min, 80-95%; and 15-17 min, 95%.  The flow rate was 0.2 
ml/min.  The HPLC eluate was directly introduced to ESI source of QTRAP5500 mass analyzer 
(ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35 psi, GS1: 35 psi, 
GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V, Collision gas: low, Declustering 
Potential: -60 V, and Entrance Potential: -7 V.  The eluate was monitored by Multiple Reaction 
Monitoring method to detect unique molecular ion – daughter ion combinations for each of the 
lipid mediators using a scheduled MRM around the expected retention time for each compound.  
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Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials (7 – 10 V) were 
used for each MRM transition.  Spectra of each peak detected in the scheduled MRM were 
recorded using Enhanced Product Ion scan to confirm the structural identity.  The data was 
collected using Analyst 1.6.2 software and the MRM transition chromatograms were quantitated 
by MultiQuant software (both from ABSCIEX).  The internal standard signals in each 
chromatogram were used for normalization, recovery, as well as relative quantitation of each 
analyte. 
Animal studies 
All animal procedures were performed according to the NIH and institutional guidelines, 
and were approved by the Wayne State University Animal Use and Care Committee.  C57BL/6 
mice (8 weeks old male, Jackson Laboratory) were used in this study.  To examine the role of 
ADRB3/HSL signaling in the regulation of COX-2 expression, mice were intraperitoneally (i.p.) 
injected with the selective HSL inhibitor, BAY 59-9435 (30 mg/kg), celecoxib (100 mg/kg body 
weight), or vehicle controls as previous described (83,116,117).  One hour later, mice were i.p. 
injected with 10 nmol of CL 316-243 or saline for an additional 3 hours (83,117).  The mice were 
euthanized and the epididymal white adipose tissue (EWAT) pads were collected and processed 
for biochemical and immunohistochemical analysis as described below. 
Real-time PCR 
Total RNA was isolated from cultured cells using Trizol and was reversely transcribed with 
an oligo-dT primer (Promega) by M-MLV Reverse Transcriptase (Promega) for first strand cDNA 
synthesis.  Total RNA was isolated from the EWAT using liquid nitrogen and a mortar and pestle 
to grind the tissue into a powder and then Trizol was added.  Then, the RNA was reversely 
transcribed with an oligo-dT primer (Promega) by M-MLV Reverse Transcriptase (Promega) for 
first strand cDNA synthesis.  For real-time PCR quantitation, 50 ng of reversely transcribed cDNAs 
were amplified with the ABI 7500 system (Applied Biosystems) in the presence of SYBR Green 
master mix.  The PCR primer pairs used were: mouse PTGS1 (COX-1): sense, 5’ – ACA AAA 
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GAA CCC AGT GTC CA – 3’, anti-sense, 5’ – AGA ACT GTG GTG GTT TCC AA – 3’; mouse 
PTGS2 (COX-2): sense, 5’ – TGA TCG AAG ACT ACG TGC AA – 3’, anti-sense, 5’ – GTG AGT 
CCA TGT TCC AGG AG – 3’; mouse CCL2: sense, 5’ – CAC AGT TGC CGG CTG GAG CAT – 
3’; anti-sense, 5’ – GCT TCT TTG GGA CAC CTG CTG C – 3’; mouse IL-6: sense, 5’ – ATG CTG 
GTG ACA ACC ACG GCC – 3’, anti-sense, 5’ – AAG CCT CCG ACT TGT GAA GTG G – 3’; 
mouse Mac-2: sense, 5’ – AGG AGA GGG AAT GAT GTT GCC – 3’, anti-sense, 5’ – GGT TTG 
CCA CTC TCA AAG GG – 3’; mouse GAPDH: sense, 5’ – CAC CTT CGA TGC CGG GGC TG – 
3’, anti-sense, 5’ – GGC CAT GAG GTC CAC CAC CC – 3’; and rat COX-2: sense, 5’ – CGT 
GGT GAA TGT ATG AGC – 3’, anti-sense, 5’ – CGA AGG AAG GGA ATG TTG – 3’.  The qPCR 
reaction was performed by using a universal PCR Master Mix (Applied Biosystems) according to 
manufacturer’s instructions.  Relative quantification (RQ) was calculated using the SDS software 
(Applied Biosystems) based on the equation RQ= 2-ΔΔCt where Ct is the threshold cycle to detect 
fluorescence.  Ct values were normalized to the internal GAPDH standard. 
Western blot analysis 
The protein extraction procedure and western blot analysis were performed as described 
(118).  The cells were collected in ice-cold PBS using cell scrapers followed by centrifugation 
(250 × g, 5 min). The cell extracts were prepared in RIPA buffer (10 mM Tris–HCl, pH 7.4, 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing 
protease inhibitors (Calbiochem) and underwent constant agitation at 4 °C for 30 minutes. The 
epididymal white adipose tissue (EWAT) samples from mice were reconstituted in RIPA buffer 
containing protease inhibitors and sonicated until the tissue dissolved into the solution.  The 
EWAT samples were then constantly agitated at 4 °C for 30 minutes.  After centrifugation of the 
samples at 15,000 × g for 20 minutes, the supernatant was collected and the protein 
concentration was measured using a bicinchoninic acid protein assay kit with BSA as a standard. 
50 μg of protein extracts were dissolved in 2× Laemmli sample buffer, heated at 95 °C for 
5 minutes, and resolved on a 10% SDS-PAGE gel. After electrophoresis, gels were transferred 
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to nitrocellulose membranes. Subsequently, membranes were blocked in 5% non-fat dry milk (Lab 
Scientific) in TBST buffer (20 mM Tris–HCl, pH 7.4, 500 mM NaCl and 0.05% Tween-20).  
Membranes were washed and incubated with the indicated primary antibodies (1:1000 dilution) 
on a rotary shaker at 4 °C overnight. The blots were then incubated with peroxidase-conjugated 
goat anti-rabbit secondary antibody for 1 h at room temperature, and developed with enhanced 
chemiluminescent reagent (Thermo Scientific). 
Immunofluorescence Staining 
Immunofluorescent staining was performed as described (112).  After differentiated 3T3-
L1 cells were treated with or without isoproterenol (10 μM) for 15 or 30 minutes, they were fixed 
with 4% paraformaldehyde at room temperature for 30 minutes.  The cells were then 
permeabilized with 0.05% Triton X-100 and blocked with 1% bovine serum albumin for 30 
minutes.  Next, the cells were incubated with an NFĸB primary antibody (1:100) followed by an 
FITC-conjugated secondary antibody (1:500). Fluorescence images were captured by the Leica 
TCS SP5 confocal system (Leica, Wetzlar, Germany).  The nuclei were visualized by DAPI 
staining. 
Immunohistochemical staining 
The immunohistochemical staining procedure followed the protocol from the Vector 
Laboratories Vectastain Universal Elite ABC Kit (Anti-mouse IgG/Rabbit IgG, Cat. No. PK-6200).  
Briefly, mouse EWAT tissues were fixed in 10% formalin followed by paraffin embedding.  Antigen 
retrieval was performed on the paraffin sections (5 µm) in citrate buffer (10 mM citric acid, 0.05% 
Tween-20, pH 6.0) at 90⁰C for 10 min, and then deparaffinized by incubating the slides in xylene 
followed by a graded series of ethanol and then water.  Endogenous peroxidase activity was 
quenched with 0.3% H2O2 for 5 minutes.  After washes, sections were incubated with blocking 
serum (normal horse serum) for 20 minutes.  Subsequently, samples were incubated with anti-
F4/80 (1:200 dilution in PBS) at 4⁰C overnight.  The slides were then washed with PBS and 
incubated with the diluted biotinylated secondary antibody for 30 minutes.  After washing with 
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PBS, Vectastain ABC Reagent was applied to the slides for 30 minutes.  After washing with PBS, 
DAB substrate reagent was added to the slides for 10 minutes and then washed several times 
with water.  Slides were examined and analyzed using the Leica inverted microscope and the 
image acquisitions were from the SPOT Pursuit monochrome digital camera. 
Transduction of 3T3-L1-CAR Cells 
Differentiated 3T3-L1-CAR cells were serum starved overnight in serum-free DMEM 
medium and then transduced with or without a multiplicity of 200 of the replicative-deficient 
adenoviral particles carrying the COX-2 vector (provided by Dr. Andrey Sorokin, Medical College 
of Wisconsin) for 1, 2, or 3 hours.  3T3-L1-CAR cells were collected for RNA isolation and qPCR 
quantification. 
Statistical analysis 
Results are shown as mean ± SD.  Differences between various treatments were analyzed 
by ANOVA.  Statistical significance was measured by Student’s t – test.  p value < 0.01 is 















CHAPTER 3:  RESULTS 
Lipidomic characterization of eicosanoids generated by adipocyte ADRB3/HSL-mediated 
lipolysis. 
 
The low grade chronic inflammation in the adipose tissue of obese individuals is in part 
due to excessive adipocyte lipolysis, which generates numerous lipid mediators.  The identity of 
these lipolysis-produced lipid mediators is not known and their specific roles in regulating pro-
inflammatory signaling in the adipose tissue are poorly understood.  The resulting lipidomic 
profiles will fill a gap that has not yet been characterized, enhance our knowledge in the adipose 
tissue biology field, and provide new opportunities for future studies investigating the patho-
physiological roles of the lipid mediators in adipose inflammation and the associated metabolic 
diseases. 
In order to identify the bioactive lipid mediators generated by lipolysis, differentiated 3T3-
L1 mouse adipocytes were treated with isoproterenol (ISO), a nonselective beta-adrenergic 
receptor agonist, or vehicle for three hours, in order to stimulate maximal lipolysis (84).  The cell 
culture media was collected and analyzed for the presence of eicosanoids using the LC-MS/MS.  
From this experiment, I was able to acquire a lipidomic profile of the eicosanoids that were 
generated from adipocyte lipolysis.  The lipidomic analysis was performed by the Wayne State 
University Lipidomics Core Facility following published methods (114,119,120).  Out of more than 
150 fatty acyl lipids detected, the levels of approximately 63 different eicosanoids, including 
metabolites derived from cyclooxygenase, lipoxygenase, and cytochrome P450 enzymes, were 
significantly elevated in the media of adipocytes treated with ISO.  As a result, for the first time, a 
comprehensive lipidomic profile of the eicosanoids generated by ADRB3-stimulated lipolysis in 




Figure 5: Lipidomic profile of eicosanoids generated from ADRB3-stimulated lipolysis in 
mouse adipocytes. 
 
Differentiated 3T3-L1 mouse adipocytes were treated with ISO (10 µM), in order to stimulate the 
ADRB3, or PBS for 3 hours.  The media was collected and analyzed by LC-MS/MS lipidomic 
methods.  The lipidomic profile shows lipid metabolites of the cyclooxygenase (A), lipoxygenase 
(B), epoxygenase (C), and other metabolites (linoleic acid (LA), eicosapentaenoic acid (EPA), 
and docosahexaenoic acid (DHA)) (D) following treatment.  Data are from a representative 
experiment which was repeated three times with similar results.  Statistical analysis show that all 





Figure 6: Heat map of eicosanoids generated from ADRB3-stimulated lipolysis in mouse 
adipocytes. 
 
Differentiated 3T3-L1 mouse adipocytes were treated with ISO (10 µM), in order to stimulate the 
ADRB3, or PBS for 3 hours.  The media was collected and analyzed by LC-MS/ MS lipidomic 
methods.  The heat map shows lipid metabolites of the cyclooxygenase (A), lipoxygenase (B), 
epoxygenase (C), and other metabolites (linoleic acid (LA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA)) (D) following treatment.  Data are from a representative experiment 
which was repeated three times with similar results.  Statistical analysis shows that all listed lipids 
















Table 1: LC-MS/MS lipidomic characterization of eicosanoids produced from ADRB3-
mediated lipolysis. 
 
Lipid metabolites of cyclooxygenase, lipoxygenase, epoxygenase, and other pathways (linoleic 
acid (LA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) were quantitated by 
LC-MS/MS lipidomic method.  Statistical analysis shows that all listed lipids are p< 0.05 (t-test) in 
comparing control vs. ISO. 
 
T-TEST
Control 1 Control 2 Control 3 ISO 1 ISO 2 ISO 3 control ISO control ISO Ctrl vs ISO
PGA2 18.71 27.77 37.71 142.29 92.29 57.87 28.06 97.48 9.50 42.45 2.53E-02
13,14dh-15k-PGD2 7.07 11.01 10.75 38.55 30.09 23.26 9.61 30.63 2.20 7.66 5.13E-03
PGD2, D17-PGE1, & PGE2 104.32 105.35 158.99 695.02 382.20 328.84 122.88 468.68 31.27 197.82 2.02E-02
15-keto PGE2 2.25 0.60 0.92 10.27 5.84 4.58 1.26 6.90 0.87 2.99 1.74E-02
6kPGF1a 8.14 14.76 9.89 50.76 53.22 58.34 10.93 54.11 3.43 3.87 6.65E-05
PGF2a, 8-isoPGF2a & 11bPGF2a 18.70 14.79 12.57 51.11 42.23 36.42 15.35 43.25 3.10 7.40 1.92E-03
15-keto PGF2a 7.55 11.23 8.62 35.85 39.25 18.04 9.13 31.05 1.89 11.39 1.52E-02
PGJ2 & D12-PGJ2 11.43 14.90 13.11 51.22 48.82 34.50 13.15 44.85 1.73 9.04 1.98E-03
iPF-VI 2.37 3.48 3.70 8.67 6.51 5.79 3.19 6.99 0.71 1.50 8.28E-03
5-OxoETE 0.50 0.60 0.92 5.37 6.69 5.09 0.67 5.72 0.22 0.85 2.90E-04
12-OxoETE 0.50 0.60 0.92 15.20 15.54 8.96 0.67 13.23 0.22 3.71 2.12E-03
15-OxoETE 0.50 0.60 0.92 6.14 8.51 7.51 0.67 7.39 0.22 1.19 3.27E-04
15(S)-HEPE  & 14,15-EpETE 0.50 0.60 0.92 26.79 22.59 18.08 0.67 22.49 0.22 4.35 4.87E-04
5-HETE 0.50 3.27 0.92 70.39 55.90 54.54 1.56 60.28 1.49 8.78 1.68E-04
8-HETE & 8,9-EpETrE 0.50 0.60 0.92 18.67 19.86 16.41 0.67 18.31 0.22 1.75 3.29E-05
9-HETE 0.50 0.60 0.92 20.66 19.78 11.20 0.67 17.22 0.22 5.23 2.70E-03
11-HETE & 11,12-EpETrE 5.54 7.31 7.91 165.85 180.25 123.00 6.92 156.37 1.24 29.78 4.84E-04
12-HETE 4.46 0.60 4.78 51.24 32.73 31.04 3.28 38.33 2.33 11.21 3.03E-03
15-HETE & 14,15-EpETrE 2.94 0.60 7.46 47.98 47.95 43.93 3.67 46.62 3.48 2.33 2.96E-05
5(S),6(S)-DiHETE 0.50 2.49 4.98 16.32 12.41 7.34 2.66 12.02 2.24 4.50 1.61E-02
5(S),15(S)-DiHETE 0.50 0.60 0.92 8.95 3.63 3.22 0.67 5.27 0.22 3.19 3.39E-02
5(S)-HETrE 0.50 0.60 0.92 23.81 24.30 17.34 0.67 21.81 0.22 3.89 3.56E-04
13-HODE & 12,13-EpOME 17.70 26.74 18.26 78.53 57.75 79.03 20.90 71.77 5.06 12.14 1.29E-03
9(S)-HOTrE 2.27 0.60 0.92 10.91 8.27 17.28 1.26 12.15 0.88 4.63 8.06E-03
13(S)-HOTrE 0.50 0.60 0.92 11.03 9.18 10.06 0.67 10.09 0.22 0.92 3.37E-05
LXA4 4.52 7.54 12.46 32.32 21.93 16.41 8.17 23.55 4.01 8.08 2.09E-02
9-OxoODE 2.09 3.28 0.92 8.86 5.63 11.14 2.10 8.54 1.18 2.77 1.04E-02
tetranor 12-HETE 0.50 4.55 0.92 15.19 10.21 10.23 1.99 11.88 2.23 2.87 4.60E-03
5,6-EpETrE 0.50 0.60 0.92 22.31 19.56 23.44 0.67 21.77 0.22 1.99 2.66E-05
20-HDoHE & 19,20-EpDPE 0.50 0.60 0.92 4.66 3.63 2.66 0.67 3.65 0.22 1.00 3.64E-03
19,20-DiHDoPE 0.50 0.60 0.92 23.00 11.17 6.32 0.67 13.50 0.22 8.58 3.04E-02
11-HEPE & 11,12-EpETE 2.59 0.60 4.97 76.91 53.92 42.72 2.72 57.85 2.18 17.43 2.78E-03
18-HEPE & 17,18-EpETE 0.50 0.60 0.92 18.21 18.15 18.89 0.67 18.42 0.22 0.41 1.53E-07
20-HETE 3.48 2.36 4.96 88.10 72.01 59.19 3.60 73.10 1.30 14.49 5.82E-04
8,9-DiHETrE 0.50 0.60 0.92 3.99 2.79 3.14 0.67 3.31 0.22 0.61 1.10E-03
11,12-DiHETrE 0.50 0.60 0.92 19.29 10.47 9.68 0.67 13.15 0.22 5.33 7.76E-03
14,15-DiHETrE 0.50 0.60 0.92 33.51 27.08 26.31 0.67 28.97 0.22 3.95 1.23E-04
12,13-DiHOME 0.50 0.60 0.92 10.98 5.37 5.31 0.67 7.22 0.22 3.26 1.27E-02
9-HODE & 9,10-EpOME 14.48 13.84 5.52 54.62 65.29 65.28 11.28 61.73 5.00 6.16 1.93E-04
13-HODE & 12,13-EpOME 17.70 26.74 18.26 78.53 57.75 79.03 20.90 71.77 5.06 12.14 1.29E-03
5-HEPE 0.50 0.60 0.92 25.05 22.77 21.34 0.67 23.06 0.22 1.87 1.64E-05
9-HEPE 2.62 0.60 0.92 98.99 49.58 46.44 1.38 65.00 1.08 29.47 1.01E-02
8-HEPE & 8,9-EpETE 0.50 0.60 0.92 12.65 9.58 8.71 0.67 10.31 0.22 2.07 6.58E-04
4-HDoHE 0.50 0.60 0.92 7.30 9.50 7.02 0.67 7.94 0.22 1.36 3.94E-04
8-HDoHE 0.50 0.60 0.92 12.46 12.65 8.97 0.67 11.36 0.22 2.07 4.45E-04
11-HDoHE 0.50 0.60 0.92 13.51 7.49 10.55 0.67 10.52 0.22 3.01 2.41E-03
10-HDoHE 3.40 0.60 0.92 18.66 15.68 10.41 1.64 14.92 1.53 4.18 3.33E-03
13-HDoHE 0.50 0.60 3.34 8.00 8.38 7.02 1.48 7.80 1.61 0.70 1.68E-03
14-HDoHE 0.50 0.60 0.92 12.64 3.28 5.57 0.67 7.16 0.22 4.88 4.14E-02
D.1.  Metabolites of LA
D.2.  Metabolites of EPA
D.3. Metabolites of DHA
Mean SD
A.  Cyclooxygenase metabolites
B.  Lipoxygenase metabolites
C.  Epoxygenase metabolites
D.  Others
(ng/ ml) (ng/ ml) (ng/ ml)
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Next, I investigated whether the elevated levels of eicosanoids from ADRB3-stimulated 
lipolysis were regulated by the activation of hormone sensitive lipase (HSL).  HSL is a key enzyme 
in the lipolysis process and is responsible for two-thirds of the total fatty acids that are released 
during ADRB3 activation (83,84,117).  Differentiated 3T3-L1 mouse adipocytes were pretreated 
with and without BAY 59-9435 (BAY), a selective HSL inhibitor, for one hour, followed by ISO or 
vehicle for three hours (84,112).  The cell culture media was collected and analyzed for 
eicosanoids using the LC-MS/MS.  The resulting lipidomic profile revealed that the ISO-induced 
production of approximately 43 different lipids was dramatically reduced by the BAY pretreatment.  
Therefore, the generation of these lipids was dependent on both the ADRB3 and HSL activation.  
In summary, I was able to successfully identify the eicosanoids derived from ADRB3/HSL-












Figure 7: Eicosanoids generated from ADRB3-stimulated lipolysis that are dependent on 
HSL activity in mouse adipocytes. 
 
Differentiated 3T3-L1 mouse adipocytes were treated with ISO (10 µM), in order to stimulate the 
ADRB3, or PBS for 3 hours in the presence and absence of BAY 59-9435 (BAY) (10 µM), a 
specific HSL inhibitor. The media was collected and analyzed by LC-MS/MS lipidomic methods.  
The lipidomic profiles and corresponding heat maps show lipid metabolites of the cyclooxygenase 
35 
 
(A), lipoxygenase (B), epoxygenase (C), and other metabolites (linoleic acid (LA), 
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) following treatment.  Data are 
from a representative experiment that was repeated three times with similar results.  Statistical 
analysis shows that all listed lipids are p< 0.05 (t-test) in comparing control vs. ISO and ISO vs. 



























Table 2: LC-MS/MS lipidomic characterization of eicosanoids produced from ADRB3/HSL-
mediated lipolysis. 
 
Lipid metabolites of cyclooxygenase, lipoxygenase, epoxygenase, and other pathways (linoleic 
acid (LA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) were quantitated by 
LC-MS/MS lipidomic method.  Statistical analysis shows that all listed lipids are p< 0.05 (t-test) in 
comparing control vs. ISO and ISO vs. ISO + BAY. 
 
control ISO BAY BAY+ISO control ISO BAY BAY+ISO Ctrl vs ISO ISO vs ISO+BAY BAY vs ISO+BAY
PGD2 4.15 7.73 2.58 3.00 1.00 2.98 0.49 2.08 7.23E-03 1.28E-02 3.76E-01
PGD3 11.09 19.17 11.99 10.80 0.61 6.35 2.43 1.54 4.88E-02 4.74E-02 2.56E-01
PGE2 245.70 486.61 210.17 220.10 19.15 125.84 12.43 57.34 7.49E-03 8.08E-03 3.92E-01
Bicyclo PGE2 18.23 30.20 17.83 18.43 1.51 7.94 3.04 3.21 3.42E-03 7.25E-03 4.13E-01
PGE3 11.09 19.17 11.99 10.80 0.61 6.35 2.43 1.54 4.88E-02 4.74E-02 2.56E-01
PGJ2 19.67 36.89 20.34 22.81 0.60 8.42 2.27 6.62 8.24E-03 3.56E-02 2.86E-01
D12-PGJ2 19.67 36.89 20.34 22.81 0.60 8.42 2.27 6.62 8.24E-03 3.56E-02 2.86E-01
12(S)-HHTrE 0.55 15.12 0.16 0.97 0.04 7.84 0.09 0.32 2.00E-04 2.33E-04 7.09E-03
11dh-TXB3 0.13 0.31 0.21 0.10 0.07 0.17 0.14 0.09 3.37E-02 3.02E-02 1.57E-01
15-OxoETE 0.29 0.93 0.22 0.15 0.21 0.45 0.05 0.14 4.21E-03 7.44E-04 2.56E-01
5-HETE 1.02 10.47 0.56 1.76 0.29 6.30 0.35 0.37 3.11E-03 4.21E-03 7.69E-03
8-HETE 1.75 4.66 0.74 1.02 0.46 2.30 0.09 0.11 3.39E-03 9.84E-04 1.37E-02
9-HETE 0.34 1.62 0.26 0.50 0.17 0.54 0.09 0.30 3.43E-02 5.21E-02 1.26E-01
11-HETE 4.67 101.41 2.47 7.61 1.46 53.76 0.65 1.74 9.29E-05 1.06E-04 4.35E-03
12-HETE 0.71 2.53 0.74 0.61 0.19 1.03 0.13 0.28 2.70E-04 4.31E-04 2.58E-01
15-HETE 2.84 26.30 1.54 2.31 0.27 14.47 0.37 0.99 2.53E-06 5.89E-06 1.38E-01
5(S)-HETrE 1.13 6.04 0.60 1.55 0.23 2.91 0.04 0.05 1.08E-04 1.22E-04 6.74E-06
13-HODE 7.63 52.45 5.98 5.75 1.22 28.20 0.29 0.36 3.04E-04 2.49E-04 2.23E-01
13(S)-HOTrE 1.23 2.41 0.65 0.83 0.34 0.94 0.21 0.15 4.16E-02 1.56E-02 1.41E-01
9-OxoODE 0.19 0.89 0.09 0.15 0.23 0.42 0.06 0.09 3.11E-03 1.34E-04 2.09E-01
13-OxoODE 0.31 4.81 1.76 0.48 0.13 2.52 2.52 0.17 3.75E-05 4.91E-05 2.14E-01
19,20-EpDPE 0.59 2.28 0.30 0.33 0.07 1.12 0.07 0.09 9.46E-06 7.66E-06 3.44E-01
11,12-EpETE 1.82 9.11 2.15 2.43 0.81 5.61 0.62 1.04 3.92E-02 4.97E-02 3.54E-01
14,15-EpETE 0.13 0.56 0.15 0.06 0.08 0.19 0.08 0.02 1.39E-02 6.67E-03 8.42E-02
17,18-EpETE 0.61 2.96 0.78 1.15 0.19 1.72 0.58 0.58 1.07E-02 3.22E-02 2.39E-01
8,9-EpETrE 1.38 3.33 1.54 1.13 0.23 1.32 0.59 0.45 1.64E-02 1.38E-02 1.99E-01
11,12-EpETrE 1.98 19.20 0.33 0.32 2.80 10.30 0.07 0.17 4.40E-04 2.96E-05 4.78E-01
14,15-EpETrE 3.01 8.07 2.46 2.33 0.19 3.22 1.09 1.17 4.27E-03 4.97E-03 4.47E-01
19,20-DiHDoPE 2.44 9.44 0.80 2.63 0.56 3.99 0.45 0.67 5.59E-03 6.32E-03 8.37E-03
18-HEPE 1.19 8.33 0.59 1.45 0.42 4.49 0.31 0.31 6.41E-03 7.14E-03 1.41E-02
5,6-DiHETrE 0.61 2.50 0.41 0.31 0.24 1.02 0.18 0.10 1.34E-02 7.56E-03 2.33E-01
8,9-DiHETrE 0.47 1.12 0.34 0.48 0.16 0.43 0.08 0.08 1.19E-03 1.22E-04 4.23E-02
11,12-DiHETrE 0.96 5.17 0.60 0.88 0.17 3.23 0.11 0.35 5.91E-03 5.86E-03 1.27E-01
9,10-DiHOME 0.42 1.22 0.29 0.20 0.11 0.61 0.07 0.17 1.44E-03 9.97E-04 2.09E-01
9,10-EpOME 3.90 18.09 5.26 2.81 3.29 8.32 0.97 2.36 1.60E-03 5.43E-04 8.58E-02
12,13-EpOME 2.33 10.06 2.19 3.62 1.78 5.25 1.96 2.66 2.31E-03 1.10E-02 2.47E-01
9-HODE 3.26 43.01 2.71 3.38 0.88 24.41 0.52 1.13 1.47E-04 1.53E-04 2.05E-01
5-HEPE 1.05 6.27 1.06 1.19 0.40 2.88 0.15 0.15 1.84E-03 1.80E-03 1.84E-01
8-HEPE 0.45 2.50 0.42 0.32 0.18 1.30 0.06 0.33 1.99E-02 1.80E-02 3.24E-01
9-HEPE 0.33 1.67 0.28 0.32 0.07 0.85 0.09 0.13 1.09E-02 1.12E-02 3.47E-01
11-HDoHE 0.48 1.68 0.18 0.25 0.08 0.71 0.11 0.12 5.68E-03 3.29E-03 2.49E-01
10-HDoHE 0.17 0.90 0.09 0.20 0.09 0.56 0.06 0.08 9.45E-03 1.06E-02 5.74E-02
15(S)-HEDE 0.07 0.46 0.09 0.06 0.02 0.19 0.06 0.003 3.62E-04 2.91E-04 1.70E-01




D.3.  Metabolites of DHA
A.  Cyclooxygenase metabolites
B.  Lipoxygenase metabolites
C.  Epoxygenase metabolites
D.1.  Metabolites of LA
D.  Others
D.2.  Metabolites of EPA
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Lipolysis-stimulated cyclooxygenase pathway, involving cyclooxygenase-2 up-regulation, 
in adipocytes and adipose tissue 
 
The cyclooxygenase (COX) enzyme and its metabolites have been shown to be up-
regulated in inflammatory states and play a role in the pathogenesis of diseases, including 
rheumatoid arthritis and gastric and colon cancers.  As previously described, the production of 
COX metabolites was shown to be significantly up-regulated in response to ADRB3/HSL-
mediated lipolysis in adipocytes.  This result led to my investigation of the underlying molecular 
mechanism explaining how the initiation of lipolysis causes the increased production of COX 
metabolites. 
Since the COX enzyme has two isoforms, COX-1 and COX-2, that both produce 
prostaglandins, prostacyclins, and thromboxanes from arachidonic acid, it was imperative to 
determine which isoform was responsible for generating the elevated levels of COX metabolites 
during adipocyte lipolysis.  Differentiated 3T3-L1 mouse adipocytes were pretreated with and 
without BAY for one hour, followed by ISO or vehicle for three hours.  The cells were collected 
and analyzed for COX-1 and COX-2 mRNA expression.  As a result, the ISO significantly up-
regulated the COX-2 mRNA levels.  Moreover, the BAY pretreatment diminished the ISO-induced 
COX-2 gene expression.  Therefore, the increased COX-2 mRNA expression is dependent on 
the activation of ADRB3 and HSL signaling in adipocytes.  The COX-1 mRNA expression, 
however, was unaffected by the BAY or ISO treatments.  The protein levels of COX-1 and COX-
2 in the 3T3-L1 cell lysates were also analyzed and in parallel to the mRNA results, the COX-2 
expression was significantly up-regulated in response to ISO and inhibited in conjunction with the 
BAY pretreatment, whereas, the COX-1 protein levels were not affected.  Consequently, the data 
suggests that the adrenergic stimulation of lipolysis and the subsequent activation of HSL in 




In collaboration with Dr. Emilio Mottillo from Dr. James Granneman’s lab at Wayne State 
University, I was able to validate the in vitro response of COX-2 expression to ADRB3 and HSL 
activation using C57BL/6 mice.  The C57BL/6 mice were intraperitoneally (i.p.) injected with and 
without BAY for one hour, followed by CL 316-243 (CL), a specific ADRB3 agonist, for three hours.  
The epididymal white adipose tissue (EWAT) pads of the mice were harvested at the time of 
euthanasia and analyzed for COX-2 mRNA expression.  Indeed, the COX-2 mRNA expression in 
the EWAT was significantly up-regulated in response to the CL treatment.  The up-regulation of 
COX-2 was abrogated by the BAY pretreatment.  Therefore, these results collectively suggest 
that COX-2 expression is induced by ADRB3/HSL-mediated lipolysis in cultured adipocytes and 
in the adipose tissue of mice. 
In order to show that COX-2 was the isoform responsible for generating elevated levels of 
COX metabolites during ADRB3/HSL-stimulated lipolysis, 3T3-L1 mouse adipocytes were 
pretreated with and without celecoxib, a selective COX-2 inhibitor, for one hour, followed by ISO 
for three hours.  The cell culture media was collected and analyzed for the presence of COX 
metabolites using the LC-MS/MS.  The resulting lipidomic profile showed that celecoxib eliminated 
the production of the COX metabolites induced by the ISO.  A study by Dr. Krishna Rao Maddipati 
et al,  showed that the incubation time, temperature, and composition of the culture media could 
greatly affect the stability of lipid species identified using the multiple reaction monitoring (MRM) 
LC-MS/MS method (114).  This study, along with the short half-lives of some of the lipids, may 
explain the differences in the minor lipid species that were detected in the cultured media from 
the various ADRB3-stimulation experiments described in this dissertation (e.g. 11dh-TXB3 and 
TXB2 in Figures 7 and 9, respectively).  Therefore, the data strongly indicates that the stimulation 
of ADRB3/HSL lipolysis in adipocytes causes the up-regulation of COX-2 expression and activity, 







Figure 8: Adipose ADRB3/HSL signaling pathway up-regulates cyclooxygenase-2 (COX-2), 
not COX-1, expression. 
 
Differentiated 3T3-L1 mouse adipocytes were treated with or without ISO (10 µM) for 3 hours in 
the presence and absence of a selective HSL inhibitor (BAY 59-9435, BAY (10 µM)).  mRNA 
levels of COX-2 (A) and COX-1 (B) were measured by qPCR analysis and protein levels (C) were 
assessed by Western-blotting analysis.  (D) C57BL/6 mice were intraperitoneally (i.p.) injected 
with BAY 59-9435 (BAY) (30 mg/kg) for 1 hour, followed by i.p. injection with CL 316-243 (10 
nmol).  Three hours later, the epididymal white adipose tissue (EWAT) was analyzed for COX-2 
mRNA levels by qPCR analysis.  Data represent mean ± SD of triplicate determinations.  Each 






Figure 9: Activity of COX-2 is responsible for producing elevated COX metabolites in 
response to ADRB3-stimulated lipolysis in adipocytes. 
 
Differentiated 3T3-L1 cells were pretreated with celecoxib (5 µM) or control vehicle for 1 hour, 
followed by stimulation with or without ISO for 3 hours.  Lipid metabolites of cyclooxygenase 
pathway were quantitated by LC-MS/MS lipidomic method, and shown by the lipidomic profile and 







control ISO Cel ISO+Cel control ISO Cel ISO+Cel Ctrl vs ISO ISO vs ISO+ Cel 
PGD2 1.05 6.27 0.62 1.39 0.07 0.56 0.37 0.44 8.61E-05 2.86E-04
PGD3 0.66 3.58 0.39 1.39 0.05 0.47 0.07 0.28 4.37E-04 2.33E-03
PGE2 64.08 543.49 22.38 89.64 5.59 111.57 1.59 10.99 1.75E-03 2.18E-03
Bicyclo PGE2 0.56 3.06 0.39 0.47 0.37 0.53 0.20 0.10 2.60E-03 1.15E-03
PGJ2 1.84 5.64 2.25 0.97 0.65 0.71 0.92 0.33 2.40E-03 4.88E-04
D12-PGJ2 10.35 66.55 4.53 12.81 1.51 8.82 1.48 0.38 4.05E-04 4.57E-04
12(S)-HHTrE 0.05 6.06 0.05 0.95 0.01 0.22 0.02 0.10 1.27E-06 3.43E-06




Table 3: LC-MS/MS lipidomic characterization of COX-2-generated lipid mediators in 
response to ADRB3/HSL activation in mouse adipocytes. 
 
Lipid metabolites of a cyclooxygenase pathway were quantitated by the LC-MS/MS lipidomic 
method.  P values of all shown lipid species are less than 0.05 (t-test) in comparing control vs. 




















Next, I investigated the molecular mechanism of how ADRB3-stimulated lipolysis 
regulates COX-2 expression.  As reported by Dr. Emilio Mottillo et al, ADRB3/HSL-mediated 
lipolysis activates stress kinases, such as c-Jun N-terminal kinase (JNK), in mouse adipocytes 
and adipose tissue (84).  This finding led me to investigate whether JNK had a regulatory effect 
on COX-2 expression.  Differentiated 3T3-L1 mouse adipocytes were pretreated with and without 
JNK inhibitor, SP-600125, for one hour, followed by the addition of ISO for three hours.  The cells 
were collected and analyzed for COX-2 mRNA expression.  The results showed that the ISO-
induced COX-2 expression was significantly inhibited by the JNK inhibitor, suggesting that COX-
2 expression is dependent on JNK activation in adipocyte ADRB3-mediated lipolysis.  The 
transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB), is a 
well-known downstream molecular target that is activated in response to JNK activation (121-
123).  Furthermore, the activation of NFĸB has been shown to promote COX-2 transcription (124-
127).  In order to determine whether NFĸB is activated in ADRB3-stimulated lipolysis, 
differentiated 3T3-L1 mouse adipocytes were treated with and without ISO for 0, 15 and 30 
minutes and immunostained with an antibody for NFĸB (see Figure 10B, Red).  As a result, the 
ISO treatment caused a progressive translocation of NFĸB into the nuclei of the 3T3-L1 cells, 
signified by the increased NFĸB staining in the nuclear regions of the cells.  This result indicates 
that the NFĸB is activated in response to beta adrenergic receptor-stimulated lipolysis in 
adipocytes.  To further support this finding, differentiated 3T3-L1 adipocytes were pretreated with 
BAY 11-7082, an NFĸB pharmacological inhibitor, for one hour, followed by ISO for three hours.  
The cells were collected and analyzed for COX-2 mRNA expression.  Consequently, the ISO-
induced COX-2 mRNA expression was abrogated by the NFĸB inhibitor.  Therefore, the data 
suggests that the COX-2 gene expression is induced in response to the activation of the 
JNK/NFĸB signaling pathway. 
Since JNK is known to be stimulated by fatty acids and the activation of HSL generates 
free fatty acids, including palmitic acid and oleic acid, I investigated whether HSL-signaling 
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contributes to the activation of the JNK/NFĸB pathway.  Differentiated 3T3-L1 mouse adipocytes 
were treated with palmitic acid for 0, 15, 30, and 60 minutes and the protein extracts from the 
cells were analyzed for the activation of JNK and NFĸB, as well as the expression of COX-2.  As 
indicated by their phosphorylation statuses in the western blot, the palmitic acid activated the JNK 
kinases, p54JNK and p46JNK.  Furthermore, the palmitic acid treatment caused the corresponding 
phosphorylation of IĸBα, signifying the activation of NFĸB, and the up-regulation of the COX-2 
protein.  The rapid phosphorylation of IĸBα and expression of the COX-2 protein in response to 
palmitic acid suggest substantial amplification of signals generated by JNK activation.  This data 
collectively indicate that the free fatty acids produced by the activation of HSL can stimulate the 
JNK/NFĸB/COX-2 signaling pathway in adipocytes. 
Moreover, when differentiated 3T3-L1 mouse adipocytes were pretreated with the 
pharmacological COX-2 inhibitor, celecoxib, for one hour, followed by ISO for three hours, the 
ISO-induced phosphorylation of IĸBα was diminished in the presence of celecoxib.  This result 
indicates that COX-2 activity is necessary for NFĸB activation in ADRB3-stimulated lipolysis in 
adipocytes.  The celecoxib did not affect the phosphorylation of HSL, thereby confirming that 











Figure 10: ADRB3 activation-induced COX-2 up-regulation is mediated by the JNK/NFκB 
signaling pathway.   
 
(A) Differentiated 3T3-L1 cells were treated with ISO (10 μM) in the presence and absence of a 
JNK inhibitor (SP-600125, 10 µM).  mRNA levels of COX-2 were quantitated by qPCR analysis.  
Data are mean ± SD (n=3; **, p< 0.01, t-test).  (B) Differentiated 3T3-L1 cells were treated with 
ISO for 0, 15, and 30 minutes followed by immunostaining with anti-NFκB.  Note that the ISO 
treatment progressively increases nuclear localization of NFκB (white arrows in middle and lower 
panels).  Red = NFκB, Blue = DAPI nuclear staining.  (C) 3T3-L1 cells were treated with ISO in 
the presence and absence of an NFκB inhibitor (BAY 11-7082, 10 µM).  mRNA levels of COX-2 






Figure 11: Palmitic acid activates JNK and NFκB and up-regulates COX-2 expression in 
adipocytes. 
 
Differentiated 3T3-L1 cells were treated with palmitic acid (PAL, 0.5 mM) for 0, 15, 30, and 60 
minutes.  Cellular extracts were blotted with indicated antibodies.  Lower panel, intensity of 
western-blotting were quantitated with NIH Image J software (normalized to GAPDH).  (n=3; *, p< 











Figure 12: COX-2 activity is required for NFκB activity and its inhibition does not affect 
HSL. 
 
Differentiated 3T3-L1 cells were treated with ISO (10 μM) in the presence and absence of a COX-
2 inhibitor (Cel, celecoxib, 5 µM) for 30 minutes.  Cellular extracts were blotted with indicated 
















Cyclooxygenase-2 activation regulates the recruitment and infiltration of monocytes and 
macrophages to the adipose tissue 
 
One of the hallmark characteristics of obesity and adipose inflammation is the recruitment 
and infiltration of monocytes and macrophages to the adipose tissue.  Monocyte chemotactic 
protein 1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2), a pro-inflammatory cytokine released 
by the adipocytes, is able to recruit the monocytes and macrophages to the adipose tissue.  The 
adipokine, interleukin-6 has also been associated with inflammation and obesity.  As previously 
reported by Mottillo et al, ADRB3/HSL-mediated lipolysis triggered the activation of stress kinases 
JNK and p38, which preceded the up-regulation of MCP-1/CCL2 and IL-6 in adipocytes (84).  In 
order to investigate whether the lipolysis-induced activation of JNK/NFĸB/COX-2 had any effect 
on the expression of MCP-1/CCL2 and IL-6, differentiated 3T3-L1 mouse adipocytes were 
pretreated with and without SP-600125 (JNK inhibitor), BAY 11-7082 (NFĸB inhibitor), or 
celecoxib (COX-2 inhibitor) for one hour.  The cells were subsequently treated with and without 
ISO for three hours, collected, and analyzed for MCP-1/CCL2 and IL-6 mRNA expression.  The 
JNK inhibitor significantly suppressed the ISO-induced MCP-1/CCL2 and IL-6 gene expression, 
while the p38 inhibitor had no statistical effect.  Both celecoxib and the NFĸB inhibitor considerably 
reduced the MCP-1/CCL2 gene expression that was up-regulated by the ISO treatment, but did 
not affect the IL-6 gene expression.  Therefore, the data suggests that the mRNA expression of 
MCP-1/CCL2 is regulated by the lipolysis-stimulated JNK/NFĸB/COX-2 signaling pathway in 
adipocytes. 
Next, I investigated whether up-regulated COX-2 expression was sufficient to induce 
MCP-1/CCL2 in adipocytes in the absence of lipolysis stimulation.  Since the transfection 
efficiency with plasmid cDNA in 3T3-L1 mouse adipocytes is low, 3T3-L1-CAR cells were used to 
perform the experiment.  3T3-L1-CAR cells only differ from 3T3-L1 cells in that they possess an 
adenovirus receptor.  Differentiated 3T3-L1-CAR cells were transduced with adenoviral particles 
carrying COX-2 that were generously provided by Dr. Andrey Sorokin (Medical College of 
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Wisconsin).  After qPCR analysis of the cells, I found that the MCP-1/CCL2 expression was 
significantly up-regulated in the cells transduced with adenoviral COX-2 compared to the control.  
The IL-6 mRNA expression was not significantly affected by the 3T3-L1-CAR cells transfected 
with the adenoviral COX-2.  Therefore, this result suggests that even in the absence of fatty acid 
release by ADRB3-stimulated lipolysis, COX-2 expression is sufficient in significantly inducing 























Figure 13: Lipolysis-increased MCP-1/CCL2 expression is dependent on the 
JNK/NFκB/COX-2 signaling pathway.   
 
Differentiated 3T3-L1 cells were pretreated with or without an inhibitor of JNK (SP 600125, 10 
µM) (A), p38 kinase (SB 203580, 10 µM) (B), NFκB (BAY 11-7082, 10 µM) (C), and COX-2 
(celecoxib, 5 µM) (D) for 1 hour.  Subsequently, cells were stimulated with or without ISO (10 μM) 
for an additional 3 hours.  Levels of MCP-1/CCL2 (left panels) and IL-6 (right panels) were 
quantitated by qPCR analysis.  Data represent mean ± SD of a representative experiment (n=3), 
which was repeated at least two times with similar results.  (**, p< 0.01; *, p< 0.05; NS, not 







Figure 14: COX-2 expression is sufficient in significantly inducing the expression of MCP-
1/CCL2 in the absence of acute lipolysis. 
 
3T3-L1-CAR cells were transduced with a multiplicity of 200 adenoviral particles carrying rat COX-
2 (Ad-COX-2) for the indicated times.  Expression levels of MCP-1/CCL2, IL-6 (A), and rat COX-
2 (B) were measured by qPCR analysis.  Note that ectopic expression of COX-2 significantly 



















To further investigate the role of lipolysis-triggered COX-2 activation in vivo, I i.p. injected 
C57BL/6 mice with and without celecoxib for one hour, followed by CL for three hours to stimulate 
acute ADRB3-mediated lipolysis.  The EWAT pads were harvested after the mice were 
euthanized and analyzed for COX-1, COX-2, MCP-1/CCL2, and IL-6 expression.  The COX-2 
mRNA and protein expression were significantly up-regulated in response to the CL treatment, 
whereas the expression of COX-1 was not affected.  Additionally, the CL treatment significantly 
up-regulated the gene expression levels of MCP-1/CCL2 and IL-6.  The celecoxib significantly 
diminished the ISO-induced MCP-1/CCL2 expression, but did not affect the IL-6 gene expression.  
These results support my in vitro observations and indicate that ADRB3-mediated lipolysis 












Figure 15: COX-2 activity is required for the ADRB3-stimulated MCP-1/CCL2 up-regulation 
in mouse epididymal white adipose tissue.   
 
C57BL/6 mice (male, 8 weeks old) were i.p. injected with celecoxib (100 mg/kg) or control vehicle 
for 1 hour.  Subsequently, mice were i.p. injected with or without CL 316-243 (10 nmol).  Three 
hours later, epididymal white adipose tissues (EWAT) were collected, and measured for levels of 
COX-2 (A), COX-1 (B), MCP-1/CCL2 (D), and IL-6 (E) by qPCR analysis.  (**, p< 0.01; NS, not 
statistically significant (n=5, Two-way ANOVA)).  (C) Protein levels of COX-2 and COX-1 were 










Furthermore, I examined whether ADRB3-activated lipolysis stimulated the recruitment 
and infiltration of monocytes/macrophages to the adipose tissue and whether it was mediated by 
COX-2 activity.  I analyzed the presence of monocytes/macrophages in the EWAT of the mice 
that were pretreated with and without celecoxib for one hour in the presence and absence of CL 
treatment for three hours, through immunohistochemistry.  According to the F4/80 staining of the 
EWAT, the amount of macrophages that infiltrated the EWAT in the mice that were injected with 
CL was significantly elevated compared to the control.  This result corresponds to the CL-induced 
MCP-1/CCL2 mRNA expression in the EWAT of mice.  The celecoxib pretreatment inhibited the 
CL-increased F4/80 staining in the EWAT.  The number of macrophages from multiple sections 
of EWAT was counted and is represented in Figure 16.  The gene expression of macrophage 
marker, Mac-2, in the EWAT was also shown to be significantly up-regulated in response to the 
CL treatment.  The celecoxib, in turn, abrogated the ISO-increased Mac-2 expression in the 
EWAT.  Therefore, these results suggest that the activation of COX-2 by ADRB3-mediated 
lipolysis contributes to inflammation by regulating the recruitment of monocytes/macrophages to 











Figure 16:  COX-2 activity is necessary for the ADRB3-stimulated monocyte/macrophage 
infiltration in adipose tissue.   
 
C57BL/6 mice (male, 8 weeks old) were i.p. injected with celecoxib (100 mg/kg) or control vehicle 
for 1 hour.  Subsequently, mice were i.p. injected with or without CL 316-243 (10 nmol).  Three 
hours later, epididymal white adipose tissues (EWAT) were collected.  (A) Paraffin sections (5 
µm) of EWAT were immunohistochemically stained with anti-F4/80.  a, vehicle; b, CL 316-243; c, 
celecoxib alone; d, celecoxib + CL 316-243; e and f, enlarged image of box area in a and b, 
respectively.  Arrows, infiltrated macrophages/ monocytes.  (B)  Macrophages/ monocytes 
present in each treatment (4-5 microscopic fields) were scored.  *, p< 0.05, t-test.  (C) Levels of 










In summary, the results obtained from this study collectively suggest that the fatty acids 
generated from HSL-mediated lipolysis activate the JNK/NFĸB/COX-2 signaling pathway in 
adipocytes.  The activation of COX-2 results in the production and release of prostaglandins, 
prostacyclins, and thromboxanes.  COX-2 activity also regulates MCP-1/CCL2 expression, which 
leads to the recruitment and infiltration of monocytes/macrophages to the adipose tissue.  The 
presence and activation of macrophages may promote inflammation in the adipose tissue.  
Alternatively, the recruited macrophages may buffer local fatty acid concentrations by up-taking 
fatty acids that are released during adipocyte lipolysis.  Therefore, my findings in this study 
characterize the lipid mediators derived from lipolysis in adipocytes and describe the discovery of 
a novel lipolysis-triggered pro-inflammatory cyclooxygenase pathway, involving COX-2, in the 















Figure 17: Proposed mechanism of a pro-inflammatory lipolysis-stimulated 
cyclooxygenase pathway.   
 
The model of my findings reveal a COX-2-mediated mechanism through which HSL-driven 
lipolysis stimulates the infiltration of monocytes/macrophages in the adipose tissue.  Various ways 
















CHAPTER 4:  DISCUSSION 
Excessive adipose lipolysis triggers adipose tissue inflammation and immune cell 
infiltration (84,112,128).  However, the pro-inflammatory lipid mediators produced from adipose 
lipolysis remain elusive.  Therefore, my doctoral study took on a lipidomic approach and utilized 
LC-MS/MS technology to successfully identify the eicosanoid lipid mediators generated during 
ADRB3/HSL-mediated adipose lipolysis for the first time.  The acquired lipidomic profiles included 
lipids derived from cyclooxygenase, lipoxygenase, and epoxygenase enzymes and others from 
linoleic acid, EPA, and DHA.  From my analysis, I was able to determine that in response to beta 
adrenergic stimulation, the production and secretion of approximately 63 eicosanoids were 
significantly increased in 3T3-L1 adipocytes.  Furthermore, I discovered that the generation of 43 
eicosanoids were dependent on the activation of ADRB3 and HSL in adipocyte lipolysis.  These 
lipid mediator profiles serve as novel additions to the lipidomic and adipose biology fields. 
In addition, the data obtained in this study strongly suggest that COX-2 is responsible for 
producing the elevated levels of prostaglandins, prostacyclins, and thromboxanes from 
arachidonic acid in response to beta-adrenergic activation of lipolysis in adipocytes.  COX-2 has 
been shown to be a critical inflammatory molecule that is induced in various tissues and in obese 
individuals (129-131).  Therefore, in the present study, I decided to focus on characterizing the 
involvement of COX-2 in lipolysis-triggered adipose inflammation.  The experimental results show 
that COX-2 expression is significantly induced and activated in cultured adipocytes and adipose 
tissue in response to ADRB3 activation.  The up-regulation of COX-2 was inhibited by selective 
pharmacological inhibition of HSL, indicating that the lipolysis-increased COX-2 expression is 
dependent on HSL activity.  Furthermore, this study suggests that COX-2 up-regulates MCP-
1/CCL2 production, which may play an important role in the recruitment and infiltration of immune 
cells in adipose tissue. 
As previously reported, adipose lipolysis activates JNK and p38 stress kinases, which play 
important roles in lipolysis-stimulated production of pro-inflammatory cytokines/chemokines 
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(84,112).  In the present study, I observed that beta adrenergic activation induced nuclear 
translocation of NFĸB, a known downstream molecular target of JNK and transcription factor that 
plays a key role in regulating inflammation.  Moreover, the lipolysis-induced COX-2 up-regulation 
was suppressed by pharmacological inhibitions of JNK or NFĸB.  Lipolysis is known to generate 
free fatty acids through the hydrolysis of triglycerides and the direct treatment of adipocytes with 
palmitic acid, a free fatty acid, activated the JNK/NFĸB/COX-2 signaling pathway.  Palmitic acid 
is a saturated fatty acid that is abundant in the Western diet and can contribute to adipose 
inflammation that is seen in obese individuals (132).  Although palmitic acid was the only fatty 
acid used to treat the 3T3-L1 mouse adipocytes in this study, it can be speculated that other 
saturated fatty acids and omega-6 fatty acids could also activate this pro-inflammatory signaling 
pathway.  Derivatives of DHA and EPA and other omega-3 fatty acids exert anti-inflammatory 
effects and therefore, I do not predict they would trigger this proposed cyclooxygenase pathway 
in the adipose tissue.  These results together suggest that free fatty acids produced by adipose 
lipolysis activate the JNK/NFĸB pathway, leading to COX-2 up-regulation.   
In addition, it was previously reported that the lipolysis-induced expression of IL-6 is 
mediated by JNK activation (84).  However, unlike MCP-1/CCL2, pharmacological inhibition of 
NFĸB or COX-2 had no significant effect on the lipolysis-stimulated IL-6 expression.  In this regard, 
my collaborators and I recently reported that the lipolysis-induced up-regulation of IL-6 is 
mediated by the production of sphingosine-1-phosphate, and this pathway requires the up-
regulation of sphingosine kinase 1 (SphK1) via the JNK/AP-1 pathway (112).  Collectively, these 
results indicate that the regulation of MCP-1/CCL2 and IL-6 both involve the generation of lipid 
mediators, but the specific pathways (COX-2 and SphK1) diverge following JNK activation. 
In the present study, I found that ADRB3-activated lipolysis triggered an acute infiltration 
of monocytes and macrophages in the epididymal white adipose tissues of mice.  The 
physiological or patho-physiological significance of the lipolysis-driven monocyte/macrophage 
infiltration warrants future investigation.  Our previous studies suggest that the lipolysis-driven 
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infiltration of monocytes/macrophages regulates inflammation, apoptosis, and remodeling of 
adipose tissues (83,84,112,133).  In addition, it has been suggested that adipose macrophages 
can buffer local fatty acid concentrations through the uptake of fatty acids and suppression of 
adipocyte lipolysis (134).  Pretreatment of the selective COX-2 inhibitor, celecoxib, prevented the 
recruitment and infiltration of the majority of the macrophages in the adipose tissue.  Therefore, 
for the first time, it has been discovered that ADRB3/HSL-mediated lipolysis initiates a 
cyclooxygenase pathway, via COX-2, that contributes to inflammation in the adipose tissue. 
The mechanism of how COX-2 could potentially regulate the expression of MCP-1/CCL2 
in adipocytes is not yet known.  The lipidomic analysis showed that prostaglandin E2 (PGE2), a 
pro-inflammatory prostaglandin involved in numerous inflammatory processes (135-138), is one 
of the most abundant lipidomic metabolites generated from the COX-2 enzyme during lipolysis.  
PGE2 is able to exert its signaling effects by binding to its own family of G protein coupled 
receptors, EP-1, EP-2, EP-3, and EP-4.  In addition, it has been reported that PGE2 treatment 
up-regulates MCP-1/CCL2 expression in mesangial cells (139).  However, I was unable to 
demonstrate that the exposure of 3T3-L1 adipocytes to PGE2 alone (up to 50 µM for up to 24 
hours) could up-regulate MCP-1/CCL2 (not shown).  Furthermore, experimental attempts using 
various combinations of other prostaglandins (e.g. PGD2, PGJ2, d12-PGJ2, 0-25 µM) to treat 
3T3-L1 adipocytes were also ineffective.  It is possible that exogenous PGE2 suppresses COX-
2-dependent pro-inflammatory signaling by activating the EP-4 receptor (140,141).  Thus, it can 
be speculated that either a combination of prostaglandins and/or other lipid mediator(s) could be 
responsible for the COX-2-mediated up-regulation of MCP-1/CCL2.  Alternatively, it is possible 
that the up-regulation of MCP-1/CCL2 is mediated by intracellular effects of the eicosanoids 
generated by the COX-2 pathway.  Future studies are needed to expose the molecular link 




In this study, the celecoxib treatment alone was observed to slightly, but significantly, 
increase levels of COX-2, MCP-1/CCL2, and IL-6 in the epididymal white adipose tissues of mice 
(see Figure 15).  The mechanism for elevated expression of those adipose inflammatory markers 
by COX-2 inhibition alone is currently unknown.  I found that a noticeable quantity of PGE2 is 
secreted by cultured adipocytes, and this level of PGE2 was significantly reduced by celecoxib 
treatment (Figure 9 and Table 3).  As discussed earlier, PGE2 was shown to suppress lipolysis 
(140-143).  Thus, it is possible that the basal level of PGE2 secreted by adipocytes functions to 
suppress adipose lipolysis and inflammation, and this process would be reversed somewhat by 
COX-2 inhibition. 
Another aspect of the study that is currently unknown is the source of the arachidonic acid 
that served as the substrate for the production of the majority of the eicosanoids.  In most cells, a 
major source of arachidonic acid is stored in its esterified form within the cell membrane.  In 
response to external stimuli, phospholipase A2 (PLA2), cleaves the phospholipids in the cell 
membrane which releases arachidonic acid into the cytosol where it can be metabolized to form 
different eicosanoids.  Arachidonic acid can also be incorporated in triglycerides that are stored 
in the lipid droplets of adipocytes.  When lipolysis is initiated, triglycerides are hydrolyzed resulting 
in the release of free fatty acids, including arachidonic acid.  The free form of arachidonic acid 
can be used as a substrate for the biosynthesis of pro-inflammatory lipid mediators by the COX, 
LOX, and cytochrome P450 enzymes.  One strategy that tests the hypothesis that the source of 
the arachidonic acid used as the substrate for COX-2 could originate from triglycerides, involves 
using stable isotopic labeling of arachidonic acid to treat 3T3-L1 adipocytes (144).  The 
incorporation of the labeled arachidonic acid into the triglycerides stored in the lipid droplets and 
its fate in response to cellular manipulation can be tracked.  If the elevated levels of COX 
metabolites generated from ADRB3-stimulated lipolysis possess the isotopic label from the 
arachidonic acid that was used to treat the 3T3-L1 cells, then it can be concluded that the 
61 
 
substrate for COX-2 originated from arachidonic acid in the triglycerides that was released during 
the lipolysis process. 
Although the ADRB3/HSL signaling pathway is a well-established model to study lipolysis 
in mice, the minute amounts of ADRB3 detected in humans is not effective in regulating lipolysis.  
Therefore, the ADRB3 itself cannot be an option for a therapeutic target in humans.  The results 
from this study still have merit, however, as the lipolysis process in mice and humans involves 
the activation of the beta-adrenergic or glucagon receptors and the subsequent activation of PKA.  
The lipidomic profiles and the lipolysis-initiated pro-inflammatory cyclooxygenase pathway in this 
study were obtained from mice and it is imperative to confirm the results in humans before moving 
forward to drug discovery and therapeutic intervention.  A variety of non-steroidal anti-
inflammatory drugs (NSAIDs) are currently available on the market and prescribed to individuals 
suffering from hypertension and inflammatory diseases, such as rheumatoid arthritis.  However, 
to my knowledge, there are no studies that link the effect of NSAIDs to lipolysis-induced adipose 
inflammation in obesity.  The novel results from this study can be used as a platform to propel 
future research by providing avenues for targeting lipolytic-specific COX-2 products that are up-
regulated in obesity. 
My doctoral research project significantly impacts the lipidomic field, especially as it relates 
to adipose tissue inflammation.  The bioactive lipid profiles revealing the eicosanoids generated 
and released upon stimulation of lipolysis add a new dimension to our overall understanding of 
lipidomics and adipose tissue biology.  Scientific researchers that have an interest in a specific 
lipid or class of lipids are now able to reference the lipidomic profiles acquired in this study and 
use this information to guide their future research projects.  The discovery of a new lipolysis-
stimulated pro-inflammatory cyclooxygenase mechanism, involving COX-2, advances our 
understanding of the molecular players involved in the lipolytic process and their patho-
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Adipose lipolysis triggers pro-inflammatory responses that play critical roles in insulin 
resistance and associated metabolic syndrome.  However, pro-inflammatory mediators generated 
by adipose lipolysis, particularly in the context of lipid mediators, are poorly defined.  In this study, 
the activation of the beta-3 adrenergic receptor (ADRB3)/hormone sensitive lipase (HSL) 
pathway, a well-employed model system, was utilized to characterize the pro-inflammatory lipid 
mediators generated by adipose lipolysis.  Cultured adipocytes were treated with an ADRB3 
agonist and the media was analyzed for eicosanoids using the LC-MS/MS lipidomic method.  
Among the characterized eicosanoids, I found that approximately 43 metabolites generated by 
cyclooxygenase (COX), lipoxygenase, and cytochrome P450 enzymes were significantly 
produced in response to ADRB3/HSL-stimulated lipolysis in adipocytes.  Mechanistically, I 
observed that lipolysis induced cyclooxygenase 2 (COX-2), not COX-1, expression in an HSL-
dependent manner in adipocytes and in the epididymal white adipose tissue (EWAT) of C57BL/6 
mice that were injected with a specific ADRB3 agonist, CL-316243 (CL).  Additionally, JNK and 
NFκB are activated by ADRB3-mediated lipolysis and regulate the increased COX-2 expression.  
Moreover, treatment with a pharmacological COX-2 inhibitor, celecoxib, decreased the COX 
metabolites in the media of ADRB3-stimulated adipocytes.  Inflamed adipose tissue involves the 
increased presence and activation of macrophages that are recruited to the tissue by the pro-
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inflammatory cytokine, MCP-1/CCL2.  Interestingly, not only was MCP-1/CCL2 expression 
significantly increased in ADRB3/HSL-mediated lipolysis, but its expression was also dependent 
on JNK/NFκB/COX-2 activation.  Furthermore, I observed that celecoxib pretreatment 
significantly blocked macrophage infiltration in the EWAT of mice treated with CL.  In summary, I 
have shown for the first time that ADRB3/HSL signaling activates a pro-inflammatory 
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